It Takes Two: Tango Therapeutics Leverages Synthetic Lethality in Precision Cancer Medicines

The biotechnology company is expanding genetically targeted therapies to tumor suppressor gene loss and cancer cell immune evasion.

0

Based in Cambridge, MA, Tango developed a cutting-edge CRISPR-based functional genomics target discovery platform and a robust bio-analytic pipeline that combined targets, pathways, genetic context, and functional data to identify novel synthetic lethal targets for the loss or inactivation of multiple tumor suppressor genes. Their growing pipeline consists of programs for genetically defined subsets of cancers with limited treatment options . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articleA CRISPR Kitty? Gene Editing Breathes New Life into the Hypoallergenic Cat
Next articleNasal Spray for Prevention/Early Treatment of COVID-19 Works in Mice